The role of neoadjuvant chemotherapy for patients with variant histology muscle invasive bladder cancer undergoing robotic cystectomy: Data from the International Robotic Cystectomy Consortium.

Journal: Urologic oncology
PMID:

Abstract

OBJECTIVE: To assess the role of neoadjuvant chemotherapy (NAC) before robot-assisted radical cystectomy (RARC) for patients with variant histology (VH) muscle-invasive bladder cancer (MIBC).

Authors

  • Ian Cooke
    Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Nassib Abou Heidar
    American University of Beirut Medical Center, Beirut, Lebanon.
  • Abdul Wasay Mahmood
    Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Ali Ahmad
    Department of Microbiology, University of Veterinary And Animal Sciences Lahore, Pakistan.
  • Zhe Jing
    1 A.T.L.A.S (Applied Technology Laboratory for Advanced Surgery) Program, Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Michael Stöckle
    University of the Saarland, Homburg Saar, Germany.
  • Andrew A Wagner
    Department of Urology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Morgan Rouprêt
    Centre de Recherche sur les Pathologies Prostatiques, Paris, France; GRC No. 5 Predictive Onco-Urology, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne Université, Paris, France.
  • Eric Kim
  • Nikhil Vasdev
    Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Hertfordshire, UK. nikhilvasdev@doctors.org.uk.
  • Derya Balbay
    Koç University Hospital, Istanbul, Turkey.
  • Koon Ho Rha
    Department of Urology, Yonsei University College of Medicine, Seoul, Korea.
  • Ahmed Aboumohamed
    Montefiore Medical Center (Albert Einstein College of Medicine), New York, NY.
  • Prokar Dasgupta
  • Thomas J Maatman
    Metro Health Hospital, Wyoming, Michigan, USA.
  • Lee Richstone
    Arthur Smith Institute for Urology, New York, NY.
  • Peter Wiklund
    Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden.
  • Franco Gaboardi
    Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Qiang Li
    Department of Dermatology, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • Ahmed A Hussein
    Department of Urology, Applied Technology Laboratory for Advanced Surgery (ATLAS) Program at Roswell Park Cancer Institute, Buffalo, NY; Department of Urology, Cairo University, Cairo, Egypt.
  • Khurshid Guru
    Roswell Park Comprehensive Cancer Center, Buffalo, NY. Electronic address: Khurshid.Guru@roswellpark.org.